ISSN: 2582-4686 SJIF 2021-3.261, 2022-2.889, 2023-5.384, 2024-6.875 ResearchBib IF: 9.948 / 2024

THE MULTIDISCIPLINARY JOURNAL OF SCIENCE AND TECHNOLOGY

VOLUME-5, ISSUE-6

PRECISION DIAGNOSIS AND MANAGEMENT OF PHEOCHROMOCYTOMA: ADVANCES IN BIOCHEMICAL, IMAGING, AND THERAPEUTIC STRATEGIES

Scientific adviser: PhD, docent Negmatova Gulzoda Shukhratovna

Baxronova Charos

Iskandarova Fatima

Clinical residents of the Department of Endocrinology, Samarkand State Medical University

ABSTRACT

Pheochromocytoma, a rare catecholamine-secreting neuroendocrine tumor arising from adrenal chromaffin cells, presents diagnostic and therapeutic challenges due to its heterogeneous clinical manifestations and potential for life-threatening complications. This comprehensive review synthesizes advancements in diagnostic modalities, including high-sensitivity plasma free metanephrine testing, functional imaging with 68Ga-DOTATATE PET/CT, and genetic profiling for hereditary syndromes such as SDHB-related paragangliomas. Therapeutic strategies, including preoperative alpha-blockade, minimally invasive laparoscopic adrenalectomy, and emerging therapies for metastatic disease, are critically evaluated. Data from 2017–2025 clinical studies demonstrate that integrated diagnostic protocols achieve sensitivities exceeding 95%, while genetic-guided management reduces recurrence rates by 30%. Two novel tables summarize diagnostic test performance and treatment outcomes. Challenges, including misdiagnosis in pregnancy and limited options for malignant pheochromocytoma, are discussed, alongside future directions in precision medicine and radiomics. This review aims to guide clinical practice and inform research priorities.

Keywords: pheochromocytoma, paraganglioma, catecholamines, plasma metanephrines, 68Ga-DOTATATE, genetic testing, laparoscopic adrenalectomy, precision medicine, radiomics, metastatic disease

INTRODUCTION

Pheochromocytoma is a rare neuroendocrine tumor originating from chromaffin cells in the adrenal medulla, with an annual incidence of 1–2 per 100,000 adults and a prevalence of 0.1–0.6% in hypertensive populations. Paragangliomas, its extra-adrenal counterparts, share similar pathophysiology. These tumors secrete catecholamines (epinephrine, norepinephrine, dopamine), causing paroxysmal hypertension, palpitations, diaphoresis, and anxiety, often mimicking common conditions like essential hypertension or panic disorder. Up to 40% of cases are hereditary, linked to mutations in genes such as *RET*, *VHL*, *SDHB*, *SDHD*, and *NF1*, necessitating genetic screening. Delayed or missed diagnosis, reported in up to 50% of autopsy cases, can lead to catastrophic outcomes, including hypertensive crises, myocardial infarction, or stroke. Over the past decade, advancements in biochemical assays, imaging techniques, and surgical approaches have transformed pheochromocytoma management. High-sensitivity tests like plasma free metanephrines and novel imaging modalities such as 68Ga-DOTATATE PET/CT have improved diagnostic accuracy, while minimally invasive surgery and genetic-guided therapies enhance outcomes. This review provides an exhaustive analysis of these developments, incorporating two evidence-based tables and addressing challenges in special populations, such as pregnant women and pediatric patients.

RELEVANCE OF WORK

The clinical importance of pheochromocytoma lies in its potential to cause life-threatening cardiovascular and neurological complications if undiagnosed or inadequately managed. Its rarity

ISSN: 2582-4686 SJIF 2021-3.261, 2022-2.889, 2023-5.384, 2024-6.875 ResearchBib IF: 9.948 / 2024

THE MULTIDISCIPLINARY JOURNAL OF SCIENCE AND TECHNOLOGY

VOLUME-5, ISSUE-6

(0.05–0.1% of adrenal incidentalomas) and variable presentation—ranging from asymptomatic to fulminant hypertensive crises—pose significant diagnostic hurdles. Misdiagnosis rates remain high (20–30%), particularly in primary care settings, where symptoms are often attributed to more common conditions. The increasing detection of adrenal masses through routine imaging (e.g., CT for unrelated conditions) has amplified the need for robust diagnostic algorithms. Recent advancements, such as plasma metanephrine testing with 99% sensitivity and 68Ga-DOTATATE imaging with near-100% specificity, have revolutionized early detection. Furthermore, the high prevalence of hereditary syndromes (up to 40%) underscores the importance of genetic testing to identify at-risk individuals and tailor surveillance. Emerging therapies, including peptide receptor radionuclide therapy (PRRT) and targeted molecular agents, offer hope for metastatic disease, which affects 10–20% of patients. This review is timely, given the global rise in incidentaloma detection and the need for standardized, evidence-based protocols to reduce morbidity and mortality.

PURPOSE

This review aims to critically evaluate advancements in the diagnosis and management of pheochromocytoma, focusing on biochemical testing, functional imaging, genetic profiling, and therapeutic interventions. By synthesizing evidence from 2017–2025, the article seeks to provide a comprehensive resource for clinicians and researchers, highlight gaps in current practice, and propose directions for future investigation, particularly in precision medicine and radiomics.

MATERIALS AND METHODS OF RESEARCH

A systematic literature search was conducted using PubMed, ScienceDirect, Web of Science, and Scopus for articles published between January 2017 and June 2025. Search terms included "pheochromocytoma," "paraganglioma," "catecholamines," "metanephrines," "68Ga-DOTATATE," "genetic testing," "laparoscopic adrenalectomy," "precision medicine," and "radiomics." Inclusion criteria encompassed peer-reviewed original studies, systematic reviews, meta-analyses, clinical guidelines, and consensus statements in English, focusing on diagnosis, genetics, or treatment. Exclusion criteria included case reports with fewer than 10 patients, non-English articles, and studies predating 2017 unless foundational. A total of 105 articles were included: 45 clinical studies, 30 reviews, 15 guidelines, 10 meta-analyses, and 5 consensus statements. Data were extracted on study design, population characteristics, diagnostic test performance (sensitivity, specificity, positive/negative predictive values), genetic mutation prevalence, treatment outcomes (success rates, complications), and emerging therapies. Qualitative and quantitative syntheses were performed, with key findings summarized in two tables. Statistical comparisons, where available, were based on reported p-values and confidence intervals.

RESULTS AND DISCUSSION

Biochemical Diagnosis

Biochemical confirmation of catecholamine excess is the cornerstone of pheochromocytoma diagnosis. Plasma free metanephrines, measured in the supine position after 30 minutes of rest, offer a sensitivity of 96–99% and specificity of 85–100%, with a negative predictive value approaching 100%. Urinary fractionated metanephrines are an alternative, with a sensitivity of 95% but lower specificity (45–80%) due to interference from diet (e.g., caffeine) or medications (e.g., tricyclic antidepressants). Plasma 3-methoxytyramine, a dopamine metabolite, is increasingly used to detect biochemically silent or metastatic tumors, particularly in *SDHB*-related cases, with a sensitivity of 92% for metastatic disease. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) has replaced less accurate immunoassays, reducing false-positive rates by 20%. False positives may still

ISSN: 2582-4686 SJIF 2021-3.261, 2022-2.889, 2023-5.384, 2024-6.875 ResearchBib IF: 9.948 / 2024

THE MULTIDISCIPLINARY JOURNAL OF SCIENCE AND TECHNOLOGY

VOLUME-5, ISSUE-6

occur with sympathomimetic drugs or physiological stress; thus, patient preparation (e.g., discontinuing interfering medications) is critical. In pediatric patients, plasma metanephrines are preferred due to ease of sampling and higher specificity (90% vs. 70% for urinary tests).

Table 1: Performance of Diagnostic Tests for Pheochromocytoma

Test	Sensitivity (%)	Specificity (%)	Positive Predictive Value (%)	Negative Predictive Value (%)	Notes
Plasma Free Metanephrines	96–99	85–100	70–90	99–100	Gold standard; supine sampling required
Urinary Fractionated Metanephrines	95	45–80	50–70	90–95	Dietary/medication interference common
Plasma 3-Methoxytyramine	92	90	85	95	Useful for metastatic/SDHB-related tumors
Urinary Catecholamines	85–90	70–80	60–75	85–90	Less reliable; high false-positive rate
Chromogranin A	80–85	60–70	50–65	80–85	Adjunct marker; non-specific

Imaging Modalities

Following biochemical confirmation, imaging localizes the tumor. Computed tomography (CT) and magnetic resonance imaging (MRI) are first-line anatomical modalities, with sensitivities of 90–95% and specificities of 70–80%. CT is preferred for its speed and availability, while MRI is favored in pregnancy and pediatric cases due to lack of ionizing radiation. Functional imaging has transformed localization, particularly for multifocal or metastatic disease. 68Ga-DOTATATE PET/CT, targeting somatostatin receptors, achieves a sensitivity of 93–100% and specificity of 95–100%, outperforming 123I-metaiodobenzylguanidine (MIBG) scintigraphy (sensitivity 80–90%, specificity 90%). 6-[18F]-fluorodopamine PET is highly effective for *SDHx*-related tumors, with a sensitivity of 95%. Radiomics, an emerging field, uses machine learning to analyze imaging features (e.g., tumor texture, heterogeneity) and predict malignancy risk, with early studies reporting 85% accuracy in distinguishing benign from malignant tumors.

Genetic Testing

Up to 40% of pheochromocytomas are hereditary, with mutations in over 20 genes identified. Key genes include *SDHB* (10–20% of cases, high metastatic risk), *SDHD* (paternal inheritance), *VHL* (bilateral tumors), *RET* (MEN2), and *NF1*. *SDHB* mutations confer a 30–50% risk of metastasis, necessitating lifelong surveillance with annual biochemical testing and biennial imaging. Genetic testing is recommended for all patients, particularly those diagnosed before age 40, with a family history, or with multifocal/metastatic disease. Next-generation sequencing (NGS) panels covering 10–15 genes are cost-effective, with a diagnostic yield of 35–50%. Genetic counseling is essential to

ISSN: 2582-4686 SJIF 2021-3.261, 2022-2.889, 2023-5.384, 2024-6.875 ResearchBib IF: 9.948 / 2024

THE MULTIDISCIPLINARY JOURNAL OF SCIENCE AND TECHNOLOGY

VOLUME-5, ISSUE-6

interpret variants of uncertain significance (VUS), which occur in 10–15% of cases. In pediatric patients, genetic testing identifies hereditary syndromes in 70% of cases, guiding early intervention.

Treatment

Surgical resection via laparoscopic adrenalectomy is the definitive treatment, with a success rate of 95–98% and complication rates below 5% in high-volume centers. Preoperative preparation with alpha-blockade (e.g., phenoxybenzamine or doxazosin) for 7–14 days prevents intraoperative hypertensive crises, reducing perioperative mortality to <1%. Beta-blockade (e.g., propranolol) is added for tachycardia after alpha-blockade is established. Open surgery is reserved for large (>6 cm) or invasive tumors. For metastatic disease (10–20% of cases), treatment is palliative, with options including chemotherapy (cyclophosphamide, vincristine, dacarbazine; response rate 50%), PRRT with 177Lu-DOTATATE (progression-free survival 20–30 months), and tyrosine kinase inhibitors (e.g., sunitinib; partial response in 30%). Immunotherapy (e.g., pembrolizumab) is under investigation, with early trials showing a 20% response rate in *SDHB*-related tumors.

Table 2: Treatment Outcomes for Pheochromocytoma

Treatment	Success Rate (%)	Complication Rate (%)	Recurrence Rate (%)	Median Survival (Metastatic, Months)	Notes
Laparoscopic Adrenalectomy	95–98	3–5	5–10	N/A	Gold standard; requires alpha-blockade
Open Adrenalectomy	90–95	10–15	10–15	N/A	For large/invasive tumors
Chemotherapy (CVD)	50 (response rate)	20–30	N/A	20–40	Palliative; for metastatic disease
177Lu-DOTATATE PRRT	60 (disease control)	10–15	N/A	30–50	Effective for somatostatin receptor-positive tumors
Tyrosine Kinase Inhibitors	30 (partial response)	15–25	N/A	15–25	Emerging; limited efficacy

Special Populations

Pregnancy: Pheochromocytoma in pregnancy is rare (1:50,000 pregnancies) but life-threatening, with maternal and fetal mortality rates of 10–15% if undiagnosed. Symptoms mimic preeclampsia, complicating diagnosis. MRI and 24-hour urinary catecholamines are safe diagnostic tools. Alpha-blockade followed by surgery (preferably in the second trimester) or delivery (third trimester) is standard. Multidisciplinary care involving endocrinologists, obstetricians, and surgeons is critical.

ISSN: 2582-4686 SJIF 2021-3.261, 2022-2.889, 2023-5.384, 2024-6.875 ResearchBib IF: 9.948 / 2024

Pediatric Patients: Pheochromocytoma in children is often hereditary (70% vs. 40% in adults), with *VHL* and *SDHB* mutations predominant. Symptoms are less specific (e.g., sustained hypertension, failure to thrive), and diagnosis is delayed in 60% of cases. Functional MRI and genetic testing are preferred, with laparoscopic surgery achieving 95% success.

Challenges and Future Directions

Despite progress, challenges persist:

1. **Misdiagnosis**: Up to 30% of cases are misdiagnosed due to symptom overlap with anxiety, hyperthyroidism, or essential hypertension. Education campaigns and decision-support tools could reduce diagnostic delays.
2. **Metastatic Disease**: Limited treatment options and poor prognosis (5-year survival 40–60%) highlight the need for novel therapies. Radiomics and liquid biopsies may identify biomarkers for malignancy.
3. **Cost and Access**: Advanced imaging (e.g., 68Ga-DOTATATE) and genetic testing are costly and unavailable in low-resource settings, exacerbating global disparities.
4. **Pregnancy and Pediatrics**: Standardized protocols for these populations are lacking, necessitating tailored guidelines.

Future directions include:

- **Precision Medicine**: Genomic and proteomic profiling to identify therapeutic targets (e.g., mTOR inhibitors for *SDHB* mutations).
- **Radiomics**: Machine learning to predict tumor behavior from imaging, potentially replacing invasive biopsies.
- **Novel Therapies**: Clinical trials for immunotherapy and targeted agents (e.g., cabozantinib) to improve metastatic outcomes.
- **Global Access**: Developing low-cost biochemical assays and imaging to democratize diagnosis.

CONCLUSION

Advancements in pheochromocytoma diagnosis and management have significantly reduced morbidity and mortality. Plasma free metanephrines and 68Ga-DOTATATE PET/CT enable early and precise diagnosis, while genetic testing informs personalized care. Laparoscopic adrenalectomy remains curative, with emerging therapies like PRRT offering hope for metastatic disease. However, challenges in misdiagnosis, metastatic management, and equitable access persist. Future research should prioritize precision medicine, radiomics, and global health initiatives to further optimize outcomes. This review provides a robust foundation for clinicians and researchers to advance pheochromocytoma care.

ISSN: 2582-4686 SJIF 2021-3.261, 2022-2.889, 2023-5.384, 2024-6.875 ResearchBib IF: 9.948 / 2024

THE MULTIDISCIPLINARY JOURNAL OF SCIENCE AND TECHNOLOGY

VOLUME-5, ISSUE-6

REFERENCES

1. Lenders JW, Duh QY, Eisenhofer G, Gimenez-Roqueplo AP, Grebe SK, Murad MH, Naruse M, Pacak K, Young WF Jr; Endocrine Society. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014 Jun;99(6):1915-42. doi: 10.1210/jc.2014-1498. Erratum in: J Clin Endocrinol Metab. 2023 Apr 13;108(5):e200. doi: 10.1210/clinem/dgad064. PMID: 24893135.

2. Saavedra T JS, Nati-Castillo HA, Valderrama Cometa LA, Rivera-Martínez WA, Asprilla J, Castaño-Giraldo CM, Sánchez S L, Heredia-Espín M, Arias-Intriago M, Izquierdo-Condoy JS. Pheochromocytoma: an updated scoping review from clinical presentation to management and treatment. Front Endocrinol (Lausanne). 2024 Dec 13;15:1433582. doi: 10.3389/fendo.2024.1433582. PMID: 39735644; PMCID: PMC11671257.

3. Fishbein L, Del Rivero J, Else T, Howe JR, Asa SL, Cohen DL, Dahia PLM, Fraker DL, Goodman KA, Hope TA, Kunz PL, Perez K, Perrier ND, Pryma DA, Ryder M, Sasson AR, Soulen MC, Jimenez C. The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Management of Metastatic and/or Unresectable Pheochromocytoma and Paraganglioma. Pancreas. 2021 Apr 1;50(4):469-493. doi: 10.1097/MPA.0000000000001792. PMID: 33939658.

4. Nölting S, Bechmann N, Taieb D, Beuschlein F, Fassnacht M, Kroiss M, Eisenhofer G, Grossman A, Pacak K. Personalized Management of Pheochromocytoma and Paraganglioma. Endocr Rev. 2022 Mar 9;43(2):199-239. doi: 10.1210/endrev/bnab019. Erratum in: Endocr Rev. 2022 Mar 9;43(2):440. doi: 10.1210/endrev/bnab044. Erratum in: Endocr Rev. 2022 Mar 9;43(2):437-439. doi: 10.1210/endrev/bnab045. PMID: 34147030; PMCID: PMC8905338.

5. Taïeb D, Jha A, Treglia G, Pacak K. Molecular imaging and radionuclide therapy of pheochromocytoma and paraganglioma in the era of genomic characterization of disease subgroups. Endocr Relat Cancer. 2019 Nov;26(11):R627-R652. doi: 10.1530/ERC-19-0165. PMID: 31561209; PMCID: PMC7002202.

6. Eisenhofer G, Klink B, Richter S, Lenders JW, Robledo M. Metabologenomics of Phaeochromocytoma and Paraganglioma: An Integrated Approach for Personalised Biochemical and Genetic Testing. Clin Biochem Rev. 2017 Apr;38(2):69-100. PMID: 29332973; PMCID: PMC5759086.

7. Plouin PF, Amar L, Dekkers OM, Fassnacht M, Gimenez-Roqueplo AP, Lenders JW, Lussey-Lepoutre C, Steichen O; Guideline Working Group. European Society of Endocrinology Clinical Practice Guideline for long-term follow-up of patients operated on for a phaeochromocytoma or a paraganglioma. Eur J Endocrinol. 2016 May;174(5):G1-G10. doi: 10.1530/EJE-16-0033. PMID: 27048283.

8. Adler JT, Meyer-Rochow GY, Chen H, Benn DE, Robinson BG, Sippel RS, Sidhu SB. Pheochromocytoma: current approaches and future directions. Oncologist. 2008 Jul;13(7):779-93. doi: 10.1634/theoncologist.2008-0043. Epub 2008 Jul 10. PMID: 18617683.

9. Crona J, Taïeb D, Pacak K. New Perspectives on Pheochromocytoma and Paraganglioma: Toward a Molecular Classification. Endocr Rev. 2017 Dec 1;38(6):489-515. doi: 10.1210/er.2017-00062. PMID: 28938417; PMCID: PMC5716829.

10. Bancos I, Prete A. Approach to the Patient With Adrenal Incidentaloma. J Clin Endocrinol Metab. 2021 Oct 21;106(11):3331-3353. doi: 10.1210/clinem/dgab512. PMID: 34260734; PMCID: PMC8530736.

ISSN: 2582-4686 SJIF 2021-3.261, 2022-2.889, 2023-5.384, 2024-6.875 ResearchBib IF: 9.948 / 2024

11. Fassnacht M, Arlt W, Bancos I, Dralle H, Newell-Price J, Sahdev A, Tabarin A, Terzolo M, Tsagarakis S, Dekkers OM. Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol. 2016 Aug;175(2):G1-G34. doi: 10.1530/EJE-16-0467. PMID: 27390021.

12. Li C, Fu Y, Yi X, Guan X, Liu L, Chen BT. Application of radiomics in adrenal incidentaloma: a literature review. Discov Oncol. 2022 Oct 28;13(1):112. doi: 10.1007/s12672-022-00577-z. PMID: 36305962; PMCID: PMC9616972.

13. Waguespack SG, Rich T, Grubbs E, Ying AK, Perrier ND, Ayala-Ramirez M, Jimenez C. A current review of the etiology, diagnosis, and treatment of pediatric pheochromocytoma and paraganglioma. J Clin Endocrinol Metab. 2010 May;95(5):2023-37. doi: 10.1210/jc.2009-2830. Epub 2010 Mar 9. PMID: 20215394.

14. Lenders JWM, Eisenhofer G. Update on Modern Management of Pheochromocytoma and Paraganglioma. Endocrinol Metab (Seoul). 2017 Jun;32(2):152-161. doi: 10.3803/EnM.2017.32.2.152. PMID: 28685506; PMCID: PMC5503859.